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Abstract
Background: Serum chitotriosidase is a promising biomarker that has shown high specificity and sensitivity in
patients with sarcoidosis. The aim of this study was to investigate correlations between serum chitotriosidase,
clinical phenotypes, disease localizations and different radiological lung involvement and to identify clinical features
associated with over-expression of chitotriosidase in a large cohort of sarcoidosis patients.
Methods: Chitotriosidase activity was evaluated in a population of 694 consecutive patients (males 39%, age 55.8 ±
12.8 years). Clinical and respiratory functional characteristics, Clinical Outcome Scale (COS) classification, clinical
phenotypes proposed by the GenPhenResA project, and radiological assessment, including CT scan, were collected.
Serum sampling and clinical and functional assessments at follow-up were also included.
Results: Significantly higher chitotriosidase activity was observed in sarcoidosis patients than in healthy controls
(p < 0.0001). Evidence of lung fibrosis with reticular abnormalities and traction bronchiectasis at High resolution CT,
presence of multiple extrapulmonary sarcoid localizations and increased 24-h urinary excretion of calcium were
associated with significantly higher chitotriosidase activity (p < 0.005). Patients with remitted or minimal disease had
lower values of chitotriosidase than patients with persistent disease. At follow-up, patients who required an increase
in steroid dose showed an increase in its activity.
Conclusions: Chitotriosidase is a reliable biomarker of sarcoidosis. It is increased in patients with sarcoidosis
correlating with disease activity, severity and multiorgan dissemination. Steroid therapy tended to reduce
chitotriosidase expression, however it responded in cases of disease relapse.
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Background
Sarcoidosis is a multi-organ granulomatous disease asso-
ciated with abnormal T-lymphocyte and alveolar macro-
phage activation and migration into affected organs [1].
Since clinical course ranges from spontaneous recovery
to severe deterioration [2], specific biomarkers would be
useful to predict clinical outcome and guide therapeutic
management [3].
Chitotriosidase is a chitinase involved in defense against
chitin-containing pathogens [4]. Recent studies showed that
the immunomodulatory effects of chitotriosidase go beyond
innate immunity to involve macrophage maturation and
differentiation, non-chitin antigen presentation and direct
stimulation of many cytokines, such as IL-8 and TGF-β [5–
9]. The enzyme has been found elevated in serum and
bronchoalveolar lavage (BAL) of patients with sarcoidosis
than in patients with other interstitial lung diseases, pul-
monary tuberculosis and healthy controls [10, 11]. In sar-
coidosis patients, chitotriosidase showed higher sensitivity
and specificity than other biomarkers, including angiotensin
converting enzyme (ACE), lysozyme and soluble IL-2
receptor [11, 12]. It has been found increased in active sar-
coidosis patients [11] and showed to predict clinical
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course, steroid responsiveness and relapse of the dis-
ease [13].
The aim of the present study was to determine serum
chitotriosidase activity in a large cohort of sarcoidosis
patients in order to test its utility for identifying clinical
phenotypes, different radiological lung involvement,
extrapulmonary organ involvement, and evaluating its
reliability in patients on steroid therapy.
Materials and methods
Study population and study design
Population
Between September 2015 and October 2017, serum chito-
triosidase activity was assayed in 694 consecutive sarcoid-
osis patients (males 39%, age 55.8 ± 12.8 years) monitored
at the Regional Referral Centre for Sarcoidosis and other
Interstitial Lung Diseases, Siena, Italy. No quantifiable
chitotriosidase activity (< 10 nmol/ml/h) was detected in
25 patients (3.6%), these patients were suspected with
CHIT1 polymorphism, but they were included into ana-
lysis since no confirmatory genetic analysis was available.
Healthy volunteers control group (n = 101, 34 males, mean
age 52.2 ± 17.2 years; 73 non-smokers, 8 current smokers)
without history of respiratory diseases and not receiv-
ing any therapy was also enrolled.
Diagnosis and measurements
Sarcoidosis was diagnosed according to international ATS/
ERS/WASOG criteria [1]. All patients underwent complete
physical evaluation and pulmonary function tests (PFT) in-
cluding diffusing capacity of the lung for carbon monoxide
(DLCO) and determination of serum concentrations of ACE
and lysozyme. Combined physiological index (CPI) was cal-
culated according to Walsh et al. [14] Extra-pulmonary sar-
coid involvement (liver, spleen, chest and abdominal lymph
nodes, skin, joints, heart, central nervous system) was
assessed by specific diagnostic methods. Calcium metabol-
ism was checked by 24-h urinary calcium excretion the
same day as serum sampling.
Radiological evaluation
Chest x-ray alterations were classified according Scadding
[15]. A high resolution CT (HRCT) scan of the chest was
available for 228 patients. On the basis of the CT findings,
patients were classified as having: 1) no lung or lymph node
involvement; 2) parenchymal micronodules with or without
lymph node enlargement; 3) parenchymal micro- and
macro-nodules associated or otherwise with consolidation;
4) lung fibrosis, characterized by reticular abnormalities
with or without traction bronchiectasis.
Patient stratification
According to therapy, patients were divided into two
groups: steroid-free (n = 362) and steroid (n = 307). The
latter included patients on steroids or other specific medi-
cations for sarcoidosis. Sarcoid patients were also classi-
fied according to the clinical phenotypes proposed by
GenPhenResA [16] and, those with a follow-up of at least
5 years, with the Clinical Outcome Scale (COS) [17].
Follow-up
Clinical assessment and chitotriosidase assay was re-
peated at follow-up in a subgroup of patients (n = 416).
Patients were classified at follow-up as “improved”,
“stable” or “worse” according the physicians’ decisions
on therapy (patients whose therapy was reduced or sus-
pended were considered to have improved, patients
whose therapy was maintained unchanged were consid-
ered stable, and patients whose therapy was increased
(steroid dose or new drug added) were considered to be
worse). All data was collected retrospectively.
Chitotriosidase assay
Chitotriosidase activity was determined by a fluorimetric
method using 22 μM 4-methylumbelliferryl β D-NNN-
triacetylchitotriosidase (Sigma Chemical Co.) in citrate-
phosphate buffer, pH 5.2; 100 μl substrate was incubated
for 1 h at 37°C and the reaction was stopped with 1.4 ml
0.1 M glycine-NaOH buffer, pH 10.8, as previously de-
scribed [10, 11]. Fluorescence was read at 450 nm with a
Perkin Elmer LS40 fluorimeter (excitation wavelength
365 nm). Chitotriosidase activity in serum was expressed
in nmol/ml/h.
Statistical analysis
Data was expressed as mean ± standard deviation (M ±
SD). Comparisons between groups were performed by t-
test and one-way ANOVA with significance set at p ≤
0.05. The Pearson test was used for correlation analysis.
Contingency tables were analysed by Fisher’s exact test
and Chi-square test. Outcome analysis was performed
using the Mantel Cox test. Statistical analysis and
graphic representations of the data were obtained using
GraphPad Prism Version 5.0 software for Windows,
while ROC curves were plotted using SPSS Statistics 20.
Results
Clinical, radiological and functional parameters
Demographic data, baseline pulmonary function test
values and serum chitotriosidase, ACE and lysozyme ac-
tivities of patients with sarcoidosis (n=694) and controls
(n=101) are reported in Table 1. No significant differ-
ences in sex, age and smoking status were found be-
tween sarcoidosis patients and controls. On average, no
significant impairment of PFT parameters, including
DLCO, was found in our cohort of patients. Table 2
shows clinical, functional and laboratory data, as well as
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radiological staging and extra-pulmonary localizations of
our sarcoidosis cohort.
Chitotriosidase assay
Chitotriosidase activity was significantly higher in sarcoid-
osis patients than in healthy controls (t=5.490, p<0.0001). It
was significantly higher in both steroid-free and treated
groups of patients than in healthy controls (180.1 ± 99.2
and 168.2 ± 118.2 nmol/ml/h vs. 34.2 ± 13.8 nmol/ml/h, t=
5.588 and t=5.492, respectively; p<0.0001 for both) (Fig. 1).
The same was true for ACE levels (49.3 ± 24.2 U/l and 48.5
± 24.8 U/l vs. 34.3 ± 21.8 U/l, t=3.344, p=0.0004 and t=
2.883 p=0.004, respectively), whereas lysozyme levels were
only significantly higher in steroid-free patients than
healthy controls (5.8 ± 1.8 and 5.4 ± 2.4 mg/l vs. 4.6 ± 2.1;,
t=1.998, p=0.046 and t=1.808 p=0.0721, respectively).
In sarcoidosis patients, chitotriosidase activity and
ACE concentrations were directly correlated (r = 0.34,
p<0.0001) (Fig. 2). No significant differences were found
in chitotriosidase activity according to sex, smoking sta-
tus, age and comorbidities. Regarding specific symptoms,
exertional dyspnea (t=2.714; p=0.0068) and cough were
associated with higher chitotriosidase activity, however
the latter was only statistically significant in steroid-free
patients (t=2.287; p=0.0281).
Pulmonary function parameters did not significantly
correlate with chitotriodase activity; however, stratifying
patients according to specific patterns of alterations at
PFTs (obstructive, restrictive or mixed respiratory de-
fect), we observed that restrictive patients and those with
reduced DLCO (TLC below the 5th percentile of the
predicted value or DLCO < 75% of predicted) showed
higher chitotriosidase activity (204 ± 305 vs 157 ± 242
nmol/ml/h, t=2.180, p=0.0296 and 310.8 ± 188 vs 162 ±
174 nmol/ml/h, t=2.682, p=0.0076, respectively).
Chitotriosidase showed a significant correlation with CPI
index as well (r=0.09434, p=0.0199).
Second line therapy approach included the use of
methotrexate in 42 patients as steroid-sparing agent (27
patients) or as steroid resistant second-line treatment
(15 patients): no differences of chitrotriosidase expres-
sion were found among these subgroups.
Chitotriosidase and radiological features
Chitotriosidase activity was higher in patients with chest
X-ray stages 1, 2, 3 and 4 than in those with stage 0 (p<
0.0001).
High resolution CT evidence of lung fibrosis with re-
ticular abnormalities and traction bronchiectasis (group 4)
(n=12) was associated with significantly higher chitotriosi-
dase activity than in patients with no evidence of lung
involvement (q=4.654; p<0.001) or with only parenchymal
micronodules and lymph node enlargement (q=4.286; p<
0.01) or with parenchymal micro- and macro-nodules as-
sociated with consolidation (q=5.828; p<0.0001). Patients
with HRCT evidence of lung fibrosis showed significant
impairment of FVC, FEV1, DLCO and KCO compared to
other patients and more frequently reported dyspnea;
whereas arthralgia was more common in group 3 (paren-
chymal micro- and macro-nodules with consolidation)
and group 4. Patients with lymph node enlargement and
parenchymal micronodules (group 2) more frequently ex-
perienced an acute or subacute clinical onset of the dis-
ease (Table 3).
Chitotriosidase activity in relation to extrapulmonary
localizations and GenPhenResA phenotypes
The number of patients with at least one extrapulmonary
localization of sarcoidosis was 267 out of 694 (38.4%). They
showed significantly higher chitotriosidase activity than
Table 1 Demographic features, smoking status and biomarker assessment in the sarcoidosis cohort and healthy controls
Sarcoidosis population Controls p-value
N° 694 101
Male (%) 270 (39) 34 (33) 0.1310
Age (years) 55.8 ± 12.8 52.2 ± 17.2 0.2065
Smoking history
(pack/year)
4.4 ± 9.7 5.1 ± 11.6 0.3457
• Current (%) 49 (7) 10 (10) 0.1199
• Former (%) 225 (32.4) 25 (25) 0.1199
• Never (%) 420 (60.5) 66 (66) 0.1199
Biomarkers determination
(basal sampling)
• Chitotriosidase
nmol/ml/h
175.4 ± 89.4 34.2 ± 13.8 < 0.0001
• ACE UI/ml 48.5 ± 26.7 34.3 ± 21.8 0.0014
• Lysozyme mg/dl 5.4 ± 2.3 4.6 ± 2.1 0.0524
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Table 2 Demographic data, smoking, comorbidities and functional, radiological and clinical parameters of the sarcoidosis cohort,
divided into steroid-free and treated
Sarcoidosis steroid-free Sarcoidosis on therapy p-value
N° 370 324
Male (%) 160 (43) 128 (39.5) 0.4012
Age (years) 55.6 ± 14.9 54.2 ± 13.4 0.5978
Smoking history (pack/year) 4.8 ± 10 5.1 ± 10.4 0.1849
• Current (%) 18 (4.8) 19 (5.8) 0.4012
• Former (%) 117 (31.6) 79 (24.3) 0.4012
• Never (%) 235 (63.5) 226 (69.7) 0.4012
Biomarkers determination (basal sampling)
• Chitotriosidase nmol/ml/h 180.1 ± 99.2 168.2 ± 118.2 0.3210
• ACE UI/ml 49.3 ± 24.2 48.5 ± 24.8 0.5031
• Lysozyme mg/dl 5.8 ± 1.8 5.4 ± 2.4 0.8265
Comorbidities 228 (61.2%) 199 (61.4%) 0.7887
• Arterial Hypertension (%) 93 (25.1) 67 (20.4) 0.1624
• Diabetes Mellitus (%) 21 (5.6) 27 (8.3) 0.0578
• Osteopenia/Osteoporosis (%) 112 (30.2) 110 (33.9) 0.1875
• Thyroid disorder (%) 29 (7.8) 25 (7.7) 0.9410
• Psychiatric disorder (%) 14 (3.7) 18 (5.5) 0.2178
• GERD/Hiatal ernia (%) 32 (8.6) 31 (9.5) 0.5264
• Other (%) 29 (7.8) 33 (10.1) 0.1765
PFTs
• FVC l (%) 3.6 ± 1.1 (105.7 ± 18.2) 3.5 ± 1.1 (104.2 ± 18.4) 0.2455
• FEV1 l (%) 2.8 ± 0.9 (98.5 ± 19) 2.7 ± 1 (95.8 ± 19) 0.0945
• FEV1/FVC 76.1 ± 7.8 75.8 ± 8.7 0.6210
• TLC l (%) 6.3 ± 1.6 (110.8 ± 18.8) 6.1 ± 1.4 (109.1 ± 16.9) 0.3401
• DLCO % 83.1 ± 15.6 77.7 ± 16.9 0.002
• KCO % 92.7 ± 15.8 89.6 ± 15.8 0.0089
Radiological assessment (Scadding)
• Stage 0 (%) 177 (47.8) 116 (35) <0.0001
• Stage 1 (%) 45 (12.1) 28 (9) <0.0001
• Stage 2 (%) 56 (15.1) 67 (21) < 0.0001
• Stage 3 (%) 81 (21.8) 83 (24) <0.0001
• Stage 4 (%) 11 (2.9) 30 (10) <0.0001
Clinical assessment
• No symptoms (%) 145 (39.1) 98 (30.2) 0.0123
• Cough (%) 132 (35.6) 110 (33.9) 0.8812
• Dyspnea (%) 155 (41.8) 133 (41) 0.8120
• Asthenia (%) 118 (31.8) 119 (36.7) 0.1125
• Arthtralgia (%) 71 (19.1) 76 (23.4) 0.1198
Localizations of disease
• Isolated pulmonary 284 (76.7) 143 (44.1%) <0.0001
• Lung + extrapulmonary 55 (14.8%) 111 (34.2%) <0.0001
• Extrapulmonary only 31 (8.3%) 70 (21.6%) <0.0001
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patients with isolated pulmonary disease (t=5.257, p<
0.0001). Chitotriosidase activity tended to be progressively
higher in patients with multiple organ involvement. In par-
ticular, patients with three or more disease localizations re-
ported significantly higher chitotriosidase activity than
those with one or two localizations (q=10.79, p<0.0001 and
q=5.05, p<0.001, respectively) (Fig. 3). Extrapulmonary dis-
ease was associated with significantly increased chitotriosi-
dase activity, regardless pulmonary involvement (F=10.51;
p<0.0001). Chitotriosidase in patients with lung
Table 2 Demographic data, smoking, comorbidities and functional, radiological and clinical parameters of the sarcoidosis cohort,
divided into steroid-free and treated (Continued)
Sarcoidosis steroid-free Sarcoidosis on therapy p-value
Clinical phenotypes
• Abdominal (%) 14 (3.7) 16 (4.9) <0.0001
• OCCC (%) 12 (3.2) 20 (6.1) <0.0001
• Muscoloskeletal-cutaneous (%) 35 (9.4) 78 (24) <0.0001
• Isolated pulmonary (%) 284 (76.7) 143 (44.1) <0.0001
• Extrapulmonary (%) 25 (6.7) 67 (20.6) <0.0001
Lab parameters
• 24 h urine calcium mg/dl 177.1 ± 136.8 222.6 ± 139.9 0.0289
COS classification 247 309
• 1 (%) 49 (19.8) 0 <0.0001
• 2 (%) 50 (20.2) 0 <0.0001
• 3 (%) 33 (13.3) 0 <0.0001
• 4 (%) 29 (11.7) 0 <0.0001
• 5 (%) 31 (12.5) 0 <0.0001
• 6 (%) 55 (22.2) 10 (3.2) <0.0001
• 7 (%) 0 112 (36.2) <0.0001
• 8 (%) 0 151 (48.8) <0.0001
• 9 (%) 0 36 (11.6) <0.0001
PFT pulmonary function test, COS clinical outcome status and biomarker assessment in steroid-free and treated sarcoidosis patients, GERD gastro-esophageal
reflux disease
Fig. 1 Comparison of chitotriosidase activity in steroid-free and
treated sarcoidosis patients and healthy controls. Data expressed as
mean ± standard deviation. ***: p < 0.0001. One-way ANOVA
Fig. 2 Correlation between chitotriosidase activity and ACE levels in
the sarcoidosis cohort (n = 669) (R = 0.3513, p < 0.0001). Pearson’s
correlation coefficient
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Table 3 Demographic, clinical and functional data and biomarker assessment of sarcoidosis patients in relation to High resolution
computed tomography (HRCT) evidence of involvement
No lung involvement Lymph node + micronodular Macronodular
and consolidation
Lung fibrosis P-value
N° (%) 27 (11.8) 127 (55.9) 62 (27.1) 12 (5.6)
Male (%) 10 (39) 59 (46) 26 (42) 2 (16) 0.2063
Age yrs 57.6 ± 10.1 55.1 ± 12.7 57.3 ± 12.2 53.2 ± 12.7 0.5185
Smoking history (pack/year) 7.2 ± 11.7 3.8 ± 9 3.7 ± 9.1 8.2 ± 13.4 0.4052
• Current (%) 3 (11) 7 (5) 3 (5) 0 0.5357
• Former (%) 8 (29) 37 (29) 24 (38) 3 (25) 0.5357
• Never (%) 16 (59) 82 (65) 35 (56) 9 (75) 0.5357
Biomarkers determination
(basal sampling)
• Chitotriosidase nmol/ml/h 196.7 ± 150.9 284.2 ± 355.2 132.3 ± 119.7 666.3 ± 311 0.0005
• ACE UI/ml 51.4 ± 22.3 63.7 ± 31.3 50.1 ± 17.9 61.6 ± 26.1 0.0047
• Lysozyme mg/dl 4.5 ± 1.7 5.9 ± 2.2 5.1 ± 1.8 6.5 ± 2.4 0.0033
PFTs
• FVC l (%) 3.6 ± 0.9 (107 ± 18) 3.4 ± 1.1 (100 ± 19) 3.5 ± 1.1 (108 ± 15.3) 2.7 ± 1.1 (79.3 ± 15.8) <0.0001
• FEV1 l (%) 2.8 ± 0.8 (100.7 ± 18.7) 2.6 ± 0.9 (93.3 ± 19.8) 2.6 ± 0.9 (94 ± 15.6) 2.1 ± 0.8 (74.5 ± 17.3) 0.0013
• FEV1/FVC 77.2 ± 5.8 76.2 ± 8.6 75.1 ± 5 78.1 ± 8.2 0.3125
• TLC l (%) 6.2 ± 1.3 (109 ± 15.8) 6 ± 1.5 (105 ± 16.7) 6.2 ± 1.4 (115.4 ± 18.5) 4.6 ± 1.6 (91.5 ± 17.2) 0.0575
• DLCO % 85.3 ± 16.1 77.5 ± 14.9 79.5 ± 17.6 50.4 ± 16.2 <0.0001
• KCO % 96.3 ± 13.5 91.6 ± 19.3 89.2 ± 15.6 74.7 ± 17.8 0.0026
Clinical assessment
• No symptoms (%) 18 (66) 44 (35) 17 (27) 2 (16) 0.0018
• Cough (%) 3 (11) 36 (28) 16 (26) 4 (33) 0.2981
• Dyspnea (%) 4 (15) 54 (43) 21 (34) 8 (66) 0.0074
• Asthenia (%) 4 (15) 39 (31) 16 (26) 5 (41) 0.2497
• Arthtralgia (%) 2 (7) 32 (25) 25 (40) 4 (33) 0.0118
Clinical onset
• Asymptomatic (%) 24 (89) 72 (57) 47 (76) 10 (83) 0.0017
• Lofgren syndrome (%) 1 (3) 8 (6) 4 (6) 0 0.7808
Clinical phenotypes
• Abdominal (%) 1 (3) 14 (11) 1 (1.6) 2 (16) 0.5170
• OCCC (%) 2 (7) 7 (5) 3 (5) 0 0.5170
• Muscoloskeletal-cutaneous (%) 3 (11) 16 (12.6) 9 (14) 1 (8) 0.5170
• Isolated pulmonary (%) 21 (77) 88 (69.2) 48 (77) 9 (75) 0.5170
• Extrapulmonary (%) 0 2 (1.5) 1 (1.6) 0
COS classification 19 95 51 10
• 1 (%) 4 (21) 1 (1) 0 0 0.0002
• 2 (%) 3 (16) 3 (3) 0 0 0.0002
• 3 (%) 2 (10) 3 (3) 0 0 0.0002
• 4 (%) 2 (10) 3 (3) 3 (6) 0 0.0002
• 5 (%) 1 (5) 4 (4) 3 (6) 0 0.0002
• 6 (%) 1 (5) 9 (9) 9 (17) 2 (20) 0.0002
• 7 (%) 4 (21) 26 (21) 10 (19) 1 (10) 0.0002
• 8 (%) 2 (10) 36 (36) 22 (43) 5 (50) 0.0002
• 9 (%) 0 11 (11) 4 (8) 2 (20) 0.0002
OCCC ocular-cardiac-cutaneous-central nervous system
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involvement only was 144.1 ± 188.2 nmol/ml/h; in patients
with lung and extrapulmonary was 239.4 ± 398.6 nmol/ml/
h; in patients with extrapulmonary only was 249.5 ± 393.1
nmol/ml/h.
A correlation between chitotriosidase and 24h-urinary cal-
cium excretion was observed in both steroid-free and steroid
subgroups (r=0.4201, p<0.0001; r=0.3528; p=0.0004).
According GenPhenResA phenotypes [16], patients
with abdominal organ involvement had higher chitotrio-
sidase activity than other groups (q=8.155, p<0.0001 vs
ocular-cardiac-cutaneous-central-nervous-system; q=11.32,
p<0.0001 vs musculoskeletal-cutaneous; q=14.97, p<0.0001
vs isolated pulmonary disease; q=11.49, p<0.0001 vs extra-
pulmonary disease), while ocular–cardiac–cutaneous–cen-
tral-nervous-system (OCCC) localization showed higher
chitotriosidase activity than isolated pulmonary involvement
(q=4.494; p<0.05) (Fig. 4).
Chitotriosidase activity in relation to COS classification
The number of patients that could be classified by COS
[17] was 556: 99 were in remission (COS 1-2), 62 reported
minimal disease (COS 3-4) and 395 showed persistent dis-
ease (COS 5 to 9). Statistically significant differences in
chitotriosidase activity were found between COS-1 and
COS-5-6-8-9 (p<0.001), COS-2 and COS-5-9 (p<0.01),
COS-4 and COS-5-6-8-9 (p<0.01, p<0.05, p<0.05 and p<
0.01, respectively) and COS-7 and COS-9 (p<0.05). Clinic-
ally persistent disease was associated with significantly
higher chitotriosidase activity than minimal or remitted
disease (t=3.824, p=0.0001) (Fig. 5).
Patients with chitotriosidase activity exceeding 126.25
nmol/ml/h more frequently showed persistent disease as
defined by COS classification (sensitivity 57%, specificity
72%) and more frequently needed a higher daily dose of
steroid (48 vs 26 events, prevalence: 24.8% and 11%, re-
spectively) (Fig. 6).
Chitotriosidase activity at follow-up
Clinical assessment and chitotriosidase determination
was available at follow-up in 416 patients (175 males,
Fig. 3 Comparison of Chitotriosidase activity in Sarcoidosis patients,
classified on the basis of the number of extrapulmonary
localizations. Data expressed as mean ± standard deviation. **: p <
0.01; ***: p < 0.0001. One-way ANOVA
Fig. 4 Comparison of chitotriosidase activity in different
GenPhenResA phenotypes. 1: abdominal; 2: ocular-cardiac-
cutaneous-central nervous system; 3: muscoloskeletal-cutaneous; 4:
pulmonary; 5: extrapulmonary. Data expressed as mean ± standard
deviation. ***: p < 0.0001; *: p < 0.05. One-way ANOVA
Fig. 5 Comparison of chitotriosidase activity in relation to COS
classification. Significant differences emerged between COS 1 and
COS 5–6–8-9 patients (p < 0.0001 in all cases), COS 2 and COS 5–6-9
patients (p < 0.05, p < 0.05 and p < 0.0001, respectively), COS 4 and
COS 5–6–8-9 patients (p < 0.001, p < 0.001, p < 0.05 and p < 0.0001,
respectively), COS 5 and COS 7 patients (p < 0.05) and COS 7 and
COS 9 patients (p < 0.001). Data expressed as mean ± standard
deviation. One-way ANOVA
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age 56 ± 13.8 years) (baseline to follow-up interval: 414
± 265 days).
When physicians decided to change steroid dose or
otherwise modify therapy, a significant increase in chito-
triosidase activity was observed in "worse" patients (n=
215) (Table 4), whereas "improved" (n=47) and "stable"
(n=164) patients did not show any significant change
(Fig. 7).
Discussion
The present study offers new insights into the clinical
utility of chitotriosidase as a biomarker in patients with
sarcoidosis. Sarcoidosis is a complex, pleiotropic disease
with many phenotypes and many clinical classifications
have been proposed [18]. Numerous biomarkers have
been proposed over time in sarcoidosis, but none of
these have been universally recognized in clinical prac-
tice [19–21]. Ideal characteristics of candidate bio-
markers should be highly specific and sensitive for the
diagnosis, but more importantly, in sarcoidosis patients,
from a prognostic point of view, to discriminate among
different phenotypes and states of the diseases predicting
remission or progression [22]. In the present study we
aimed to test chitotriosidase utility for identifying clin-
ical phenotypes, different radiological lung involvement,
extrapulmonary organ involvement, and for evaluating
its reliability in a large cohort of sarcoidosis patients
with and without steroid therapy.
Chitotriosidase is a chitinase involved in defense against
chitin-containing pathogens [4]. This enzyme, implicated
in innate immunity, macrophage maturation and differen-
tiation, has been found elevated in serum and bronchoal-
veolar lavage (BAL) of patients with sarcoidosis and has
been proposed some years ago as prognostic biomarker by
our group of research [11]. It showed higher sensitivity
and specificity than other biomarkers [23–26], including
angiotensin converting enzyme (ACE), lysozyme and
soluble IL-2 receptor [11, 12] and it has been found
increased in active sarcoidosis patients [11] showing to
predict clinical course, steroid responsiveness and relapse
of the disease [13].
In the present large case series (n = 694), chitotriosi-
dase activity proved to be a reliable biomarker of sar-
coidosis; it was significantly increased in patients with
sarcoidosis than in healthy controls and it correlated
with respiratory symptoms (exertional dyspnea and
cough) and with serum ACE concentration. It also
proved to correlate with disease severity, expressed as
severe progressive pulmonary and extrapulmonary in-
volvement, to be able to detect disease relapse and to
identify patients requiring escalation of therapy.
Chitotriosidase correlated with radiological findings in
our cohort: patients with chest X-ray stages different from
0 showed significantly higher concentrations. In the
present study, we firstly investigated correlations between
chitotriosidase activity and different CT patterns of pres-
entation. Severe pulmonary involvement, indicated by
HRCT by evidence of lung fibrosis with reticular abnor-
malities and traction bronchiectasis, was associated with a
significant increase in chitotriosidase activity. In sarcoid-
osis patients, fibrosis is a result of persistent and
Fig. 6 Log-rank test comparing outcome (increase in daily dose of steroid) in sarcoidosis patients with basal chitotriosidase above or below the
cut-off of 126 nmol/ml/h. (Chi-square = 10.396; p = 0.001). Long rank test
Table 4 Changes in chitotriosidase activity between basal and
follow-up sampling, in relation to subjective symptoms and
therapy adjustments during the observation period
Δ Chitotriosidase (nmol/ml/h) p-value
Therapy modification
• Improved (n = 47) −64.5 ± 118.1 0.2045
• Stable (n = 164) −1.3 ± 214.4 0.9389
• Worsened (n = 215) 44.1 ± 131.4 0.0012
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uncontrolled disease [27] and chitotriosidase may reflect
persistent granuloma activity. We also explored Chitotrio-
sidase activity in relation the composite physiological
index (CPI), proposed by the Brompton group of research,
that showed to identify patients at high clinical risk correl-
ating with radiological extent of fibrosis [14] and we found
a slightly significant correlation with chitotriosidase activ-
ity. In our cohort strength of such correlation is rather
weak, even if significant (r = 0.09434, p = 0.0199); prob-
ably it is underestimated by the overwhelming percentage
of patients with normal PFTs. Further studies are needed
to better understand values of CPI in combination with
chitotriosidase in sarcoidosis, but indirectly suggests
the association of chitotriosidase expression with fi-
brosis development. Overexpression of chitotiosidase
has been previously associated with abnormal produc-
tion of TGF-beta, leading to initiation and perpetuation of
interstitial lung disease in systemic sclerosis [9] and its ex-
pression, and of other chitinases (i.e. YKL-40), has been
associated to airway remodelling in severe asthma [28,
29]. Moreover, in BAL from patients with sarcoidosis,
chitotriosidase has been found increased in progressive
than stable patients [11, 24]. These results suggest that
this enzyme could be involved in fibrogenesis in diffuse
lung diseases, expression of high activation of certain
macrophage pathways responsible for remodeling and fi-
brosis development.
In our study, population was divided according to Gen-
PhenReSa phenotypes classification [16], that have been
proposed to make homogenous cohorts in biomedical stud-
ies, in five subgroups: 1) abdominal organ involvement; 2)
ocular–cardiac–cutaneous–central; nervous system disease
involvement; 3) musculoskeletal–cutaneous involvement; 4)
pulmonary and intrathoracic lymph node involvement; 5)
extrapulmonary involvement [15]. We did observe that
patients with multiorgan sarcoid involvement (39% of our
population), particularly with abdominal involvement, had
higher chitotriosidase activity: patients with three or more
extrapulmonary localizations showed higher chitotriosidase.
In 2016, Popevic et al. failed to demonstrate higher chito-
triosidase levels in patients with extrapulmonary sarcoidosis
detected by PET-CT scan [23]. In the present study, the
definition of extrapulmonary involvement was based on
specific clinical, radiological and pathological investigations,
including PET-CT scan in some cases. This approach,
probably more complete and sensitive than PET-CT scan
alone, might explain our findings. Patients with active and/
or persistent disease showed increased activity of chitotrio-
sidase. Definition of sarcoidosis activity is difficult and there
is still no universal consensus. In the present study, we used
the COS classification scale proposed some years ago by
WASOG in which patients are classified in relation to need
for therapy, disease persistence, relapse of symptoms and
modification of therapy at follow-up [17]. It has been previ-
ously reported by us and others [10, 23] that chitotriosidase
activity is expressed differently among COS stages. Even if
we could not apply COS to all our population, but only to
patients with 5 or more years of follow-up at time of chito-
triosidase determination (n = 553), in the present study we
confirmed this association: patients in remission or with
minimal disease (COS stages 1 to 4) had lower chitotriosi-
dase activities than patients with persistent disease (COS
stages 5 to 9) and, among the latter, patients whose condi-
tions deteriorated showed higher activities than stable
patients.
Chitotriosidase expression showed to increase in pa-
tients with multiple organ involvement suggesting that
its level correspond to the amount of active organ in-
volvement reflecting the number of active granulomas
harbored by a patient at a given time. In a previous
paper from our group [24], we reported a significant dis-
crepancy between serum and BAL expression of chito-
triosidase suggesting the potential extrapulmonary
production of this biomarker, however in that paper
population was not such well characterized as in this
present work. Anyway, extrapulmonary production of
chitotriosidase is supported by other studies describing
Fig. 7 Line plots of Chitotriosidase activity at basal and follow-up sampling: a therapy modification, improved; b therapy modification, worsened; c
therapy modification, stable. *: 0.0012. Paired t test
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chitotriosidase as a reliable marker of macrophage acti-
vation in different organs and apparatus [30–32].
Chitotriosidase is mainly secreted by macrophages and
is involved in maturation of monocytes into both M1
and M2 macrophages subtypes, even without the pres-
ence of chitin. How chitotriosidase is implicated in
pathogenic mechanisms of sarcoidosis is unknown. The
pathogenesis of sarcoidosis is complex and not yet com-
pletely understood; environmental, genetic and immuno-
logical factors demonstrated several interactions that
lead to macrophage activation and granuloma formation.
The innate immune system has also been shown to play
a role in the triggering and maintenance of granuloma-
tous inflammatory phenomena [33]. However, the events
preventing dissolution of granulomas and maintaining
inflammation, evolving toward fibrosis are not yet fully
characterized [33] and specific studies to better under-
stand chitotriosidase role in sarcoidosis mechanisms are
lacking.
The chitotriosidase activity cut-off of 48.8 nmol/h/ml
was proposed by our research group to distinguish sar-
coid patients from healthy subjects with high sensitivity
and specificity (89 and 93%, respectively) [10]. Chitotiro-
sidase has been found overexpressed in sarcoidosis than
patients with idiopathic pulmonary fibrosis, interstitial
lung disease associated to systemic sclerosis and tuber-
colosis [24, 25], however increased levels have been also
reported in COPD, asbestosis and lung cancer patients
[26]. Diagnostic accuracy of chitotriosidase for sarcoid-
osis is still to be addressed, prospective studies evaluat-
ing its levels in patients with differential diagnosis with
sarcoidosis are strongly needed.
In the present study, we identified a second cut-off to
predict disease persistence among sarcoidosis: patients
with chitotriosidase activity higher than 126 nmol/h/ml
proved to have active disease requiring an increase in
therapy. These observations confirm the prognostic
value of this biomarker, which can identify patients most
likely to have a persistent disease and therefore requiring
particular attention. In fact, chitotriosidase analysis at
follow-up showed that patients requiring an increase in
steroid dosage showed higher chitotriosidase activity. In
line with this observation, Harlander et al. reported a
significant increase in chitotriosidase activity during re-
lapse of sarcoidosis [13]. Unfortunately, due to retro-
spective nature of this study, we could not explore
chitotriosidase in relation with quality of life as stan-
dardized specific questionnaires were not available for
the majority of patients included in the study.
The main limitations of the present study are its retro-
spective and monocentric nature and the absence of a
validation cohort. Moreover, the low number of patients
with Löfgren syndrome prevented us to explore chitotrio-
sidase in this particular subgroup of patients. However,
this is the biggest study ever conducted on chitotriosidase
in sarcoidosis and the results clearly show its potential
utility as a clinical biomarker correlating with many clin-
ical and radiological parameters. Prospective studies to
evaluate its role in clinical decision-making are needed to
definitely establish its role in sarcoidosis patients.
Conclusion
The present study demonstrated that chitotriosidase
activity is a reliable biomarker of sarcoidosis. Our results
showed that it is correlated with disease activity, severity
and multiorgan dissemination. Taken together, our find-
ings support an intriguing hypothesis that chitotriosidase
production, mainly by sarcoid macrophages [34], could
reflects the number of active granulomas harbored by a
patient at a given time. In favor of this speculation, we
observed chitotriosidase activity differently expressed in
patients with severe pulmonary involvement (presence
of lung fibrosis at CT scan), with multi vs. single organ
involvement (in particularly in patients with abdominal
involvement and with three or more extrapulmonary lo-
calizations), with active vs. non-active disease and with
remitted/minimal vs. persistent disease and in patients
at high clinical risk (expressed by CPI index). Moreover,
chitotriosidase expression reduces with steroid therapy
and it proved able to detect disease relapse and to iden-
tify patients requiring escalation of therapy. Together
with these positive clinical findings, chitotriosidase la-
boratory determination has been shown feasible, quick
and accurate with reasonable costs [35].
Combined with clinical, radiological and physiological
findings, chitotriosidase activity proved to be an excellent
non-invasive prognostic biomarker for management of pa-
tient with sarcoidosis, with a cost-benefit ratio highly posi-
tive, that should be part of the regular follow-up of
sarcoidosis patients in the daily clinical practice.
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